Skip to main content
SCNX
NASDAQ Life Sciences

Scienture Reports Q1 Revenue Surge, Patent Wins, and REZENOPY™ Market Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.395
Mkt Cap
$16.334M
52W Low
$0.238
52W High
$2.6
52W Position info
66% above low
Off High info
85% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

SCNX sits 66% above its 52-week low of $0.238 on light trading volume (0.1× avg).

Summary

Scienture Holdings reported Q1 2026 financial results highlighting significant percentage growth in revenue and gross profit, alongside new patents and expanded market access for its products, despite an increased net loss. The company also reiterated its $11.0 million non-dilutive debt financing and announced the upcoming launch of its REZENOPY™ sales force.


Key Events · Earnings and Guidance · SCNX

  • Q1 2026 Financial Results

    Revenue increased 449% year-over-year to $56 thousand, gross profit surged 7900% to $54 thousand, and gross margin expanded to 95.6%. The net loss for the quarter increased to $3.4 million.

  • Operational Milestones Achieved

    The USPTO granted a third patent for Arbli™ (losartan potassium) oral suspension, extending exclusivity through 2041, and an Orange Book-listable patent for REZENOPY™ (naloxone HCl) nasal spray 10 mg.

  • Expanded Market Access for REZENOPY™

    Formalized multiple commercial GPO agreements for REZENOPY™, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market.

  • Sales Force Launch Scheduled

    A dedicated sales force for REZENOPY™ is scheduled to begin operations on June 1, 2026, targeting key accounts and purchasing organizations.


Analysis · SCNX · Life Sciences

This 8-K furnishes a press release detailing Q1 2026 financial results and operational highlights. While the company reported an increased net loss of $3.4 million, it emphasized significant percentage growth in revenue (449% to $56K) and gross profit (7900% to $54K), alongside a substantial expansion in gross margin to 95.6%. Operationally, Scienture secured new patents for its products, expanded market access for REZENOPY™ through GPO agreements, and announced the launch of its sales force for REZENOPY™ on June 1, 2026. The filing also reiterated the $11.0 million non-dilutive debt financing previously announced. These operational advancements and revenue growth, despite the overall net loss, are important for a company that recently disclosed substantial doubt about its ability to continue as a going concern.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SCNX was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3M. The 52-week trading range was $0.24 to $2.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCNX - Latest Insights

SCNX
Oct 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.92
Real-time Price: $3.01 info
Change: +$0.090 (+3%) info
Market Cap: $4.944M info
SCNX
Oct 13, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.01 info
Change: -$1.02 (-25%) info
Market Cap: $4.944M info
SCNX
Oct 02, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1864
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $4.944M info
SCNX
Sep 30, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.220
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $4.944M info
SCNX
Sep 22, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3128
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $4.944M info